Lundbeck
- Company typePublic
- Founded1915
- HeadquartersValby, Denmark
- Headcount5,001–10,000
- GTM typeB2B
- OfferingHardware or Manufacturing
Lundbeck firmographics
Firmographics- Name
- Lundbeck
- Legal name
- H. Lundbeck A/S
- Website
- https://lundbeck.com
- Company type
- Public
- Founded year
- 1915
- Operating status
- Operating
- Headcount range
- 5,001–10,000 employees
- Ownership category
- akta.pro rank
Lundbeck industry classification
Industry- Product category
- Central Nervous System Pharmaceuticals
- SIC
- Medicinal Chemicals & Botanical Products (2833)
- akta.pro primary industry
- Neurology & CNS Specialty Pharmaceuticals (HLAIACAC)
- akta.pro secondary industries
- Headache & Migraine Medicine (HLAKAIAE), Autonomic Disorders (Dysautonomia) (HLAKAIAN), Movement Disorders (Parkinson’s, Tremor, Dystonia) (HLAKAIAC), Endocrine Hypertension & Neuroendocrine Disorders (HLAKADAN)
Keywords
Where Lundbeck is headquartered
LocationHeadquarters
- HQ city
- Valby
- HQ country
- Denmark
- HQ region
- Europe
Offices3 records
Markets served
Lundbeck business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Marketing or Sales, Operations, Supply Chain
Revenue model
- Pharmaceutical drug sales: Revenue generated from sale of prescription pharmaceutical products for neurological and psychiatric disorders. Products include Vyepti (eptinezumab) for migraine prevention, Rexulti (brexpiprazole) for schizophrenia and depression, and other CNS treatments. Revenue from both established products and newly launched drugs.
Go-to-market motion2 records
Distribution channels1 record
Marketing channels3 records
Lundbeck product offering
Product offeringCore offering
H. Lundbeck A/S is a global pharmaceutical company that researches, develops, manufactures, and commercializes prescription drugs for psychiatric and neurological (CNS) disorders. Its marketed portfolio includes Vyepti (eptinezumab) for migraine prevention, Rexulti (brexpiprazole) for schizophrenia and major depressive disorder, Abilify Asimtufii for schizophrenia and bipolar I, Trintellix (vortioxetine), and Cipralex/Lexapro (escitalopram), while its investigational pipeline targets rare epilepsies, Parkinson's disease, multiple system atrophy, Cushing's disease, and thyroid eye disease through novel mechanisms such as anti-PACAP, anti-ACTH, 5-HT2C agonism, anti-alpha-synuclein, and CD40L blockade.
Product overview
Lundbeck is a Danish pharmaceutical company focused on brain disorders, offering a portfolio of approved and investigational treatments spanning multiple therapeutic areas. Approved products include Vyepti (eptinezumab), a CGRP inhibitor for migraine prevention, alongside Rexulti, Abilify Asimtufii, Trintellix, and Cipralex/Lexapro for psychiatric conditions. The investigational pipeline includes bocunebart (anti-PACAP antibody for migraine), bexicaserin (5-HT2C agonist for rare epilepsies acquired from Longboard), amlenetug (anti-alpha-synuclein for MSA with Genmab partnership), asedebart (anti-ACTH for Cushing's disease), Lu AF28996 (D1/D2 agonist for Parkinson's), and Lu AG22515 (CD40L blocker for thyroid eye disease). The company is expanding from its neuroscience heritage into neuroendocrine and neuroimmunology indications, with strategic focus on AI-driven drug discovery through partnerships with Cradle AI, OpenAI, and Iambic Therapeutics.
Differentiator
Problem solved
Functional benefit
Brands
- Vyepti (eptinezumab): FDA-approved monoclonal antibody for migraine prevention targeting CGRP pathway
- bocunebart (Lu AG09222)
- bexicaserin
- asedebart (Lu AG13909)
- amlenetug
- Lu AF28996
Products and services
- Vyepti (eptinezumab) FDA-approved monoclonal antibody CGRP inhibitor administered via quarterly intravenous infusion for the preventive treatment of migraine in adults. Marketed in the US, Europe, and Asia (including South Korea), supported by Phase 3 SUNRISE and Phase IV RESOLUTION trial data. Reached DKK 4.48 billion (~$711M) in 2025 sales with 59% YoY growth.
- Rexulti (brexpiprazole) Atypical antipsychotic co-developed with Otsuka for the treatment of schizophrenia and as adjunctive therapy for major depressive disorder. Generated approximately DKK 6.21 billion (~$973M) in 2025 sales, up 23% YoY, and DKK 4.7B ($737M) in the first nine months of 2025. Faces US patent exclusivity expiration at end of 2028.
- Abilify Asimtufii (aripipiprazole) Once-every-two-months long-acting injectable aripiprazole formulation for maintenance therapy of schizophrenia and bipolar I disorder. Marketed in Canada with broad public reimbursement and commercially distributed through Lundbeck Canada Inc.
- Trintellix (vortioxetine)
- Cipralex/Lexapro (escitalopram)
Quantifiable outcome
- Bexicaserin showed sustained seizure reduction of 60.2% at 18 months and 53.7% at 24 months in DEE patients
- +3 more outcomes
Companies that use Lundbeck
Customer profileSegments2 records
Ideal customer profiles2 records
Lundbeck technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability5 records
Feature3 records
Lundbeck partnerships and signals
Strategic signalPartnerships
Five partnerships are on record, tiered core.
- CradlecoreMulti-year AI partnership to co-develop novel monoclonal antibody therapeutics for central nervous system disorders using closed-loop generative protein engineering approach. Integrates Cradle's AI-driven protein design platform with Lundbeck's CNS domain expertise for iterative antibody candidate design, testing, and refinement. Industry benchmarks suggest this paradigm can reduce antibody discovery timelines by 5-10 times compared to traditional methods.
- Zuellig PharmacoreExpanded partnership with Zuellig Pharma to serve as agency partner for commercializing Lundbeck's neuro-psychiatric health products including Lexapro, Brintellix, and Cipralex across Indonesia, Malaysia, Philippines, Singapore, and Taiwan. Builds on existing distribution relationship with end-to-end commercialization services.
- OpenAIcoreStrategic partnership to deploy enterprise-grade AI tools including ChatGPT Enterprise across Lundbeck's operations, focusing on neuroscience research and therapy development. Initiative aims to accelerate research, streamline analysis, and boost efficiency across the global workforce, following successful pilots.
- Contera PharmacoreResearch collaboration to advance RNA-targeting medicines for serious neurological conditions. Partnership aims to accelerate discovery of oligonucleotide-based treatments by leveraging combined expertise and proprietary platforms.
- Genmab A/ScoreJoint licensing agreement for development of amlenetug, a monoclonal antibody targeting alpha-synuclein for multiple system atrophy (MSA). Amlenetug has received Orphan Drug Designation in EU, Japan, and US, as well as Fast Track designation in US and SAKIGAKE designation in Japan. Lundbeck completed Phase III MASCOT trial enrollment ahead of schedule.
Scale indicators8 records
Recent moves6 records
Expansion highlights6 records
Lundbeck competitors and assessment
Company assessmentDirect peers
- Otsuka Pharmaceutical: Co-development partner with Lundbeck on Rexulti (brexpiprazole) for schizophrenia and MDD. Both companies share CNS focus, with Otsuka also active in psychiatry and rare-disease neurology, making it the closest direct collaboration peer in Lundbeck's core franchise.
- Jazz Pharmaceuticals: Specialty CNS pharmaceutical company with a similar commercial model targeting neurology and psychiatry via specialty sales forces. Jazz's Xywav/Epidiolex franchises and rare neurology focus closely mirror Lundbeck's neuro-rare and migraine strategies.
- UCB: Belgian specialty pharma with a strong CNS and rare-disease focus, including epilepsy (Vimpat, Keppra) and immunology. UCB's pipeline in developmental epilepsies and migraine makes it a directly comparable CNS specialty peer with overlapping patient populations.
- Neurocrine Biosciences: US CNS specialty pharma focused on neurology and psychiatry, with commercial products in movement disorders (Ingrezza) and a pipeline spanning schizophrenia, epilepsy, and rare CNS indications. Closely aligned strategic profile to Lundbeck's neuro-rare and psychiatry focus.
Broad incumbents
- Biogen: Larger established biopharmaceutical company with a strong neuroscience heritage and rare neurological disease focus (Spinraza, SMA; recently launched Reata, Skyclarys). Comparable neuroscience research infrastructure and rare neurology commercial franchise make it a broad incumbent peer.
- AbbVie: Diversified major pharma with a major CNS franchise (Vraylar for schizophrenia/MDD, Botox for chronic migraine) and a long history in neurology and psychiatry. As a broader incumbent with overlapping products in migraine and psychiatry, it represents a larger competitor in Lundbeck's core categories.
- Pfizer: Global biopharmaceutical major with broad CNS and migraine exposure (Nurtec ODT, acquired via Biohaven) and active rare-disease strategy. As a large incumbent with overlapping migraine and rare-disease ambitions, Pfizer is a broad competitive peer.
Emerging players
- Axsome Therapeutics: Emerging CNS-focused biopharma with approved products in depression (Auvelity) and migraine (Symbravo). Axsome is a smaller, faster-growing specialty player in overlapping therapeutic categories, making it a comparable emerging competitor in migraine and depression.
- Sage Therapeutics: CNS-focused biopharma developing treatments for depression, epilepsy, and other neurological conditions. The company's Zurzuvae (postpartum depression) and pipeline overlap with Lundbeck's psychiatry and rare epilepsy focus make it a relevant emerging peer.
Regional players
- Recordati: European specialty pharma with established CNS franchises across rare diseases and neurology, primarily serving EU markets. Comparable specialty-pharma business model and European commercial footprint make it a regional peer in Lundbeck's home market.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks6 records
Key highlights6 records
Customer concentration
Lundbeck social profiles
Digital presenceLundbeck financial estimates
Financial estimateRevenue estimate
Valuation estimate
Lundbeck leadership team
Management profileNumber of profiles
Profiles7 records
Lundbeck subsidiaries and ownership
Company hierarchySubsidiaries4 records
Lundbeck funding detail
Funding detailFunding overview
Funding rounds2 records
Investors1 record
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Lundbeck M&A and investment
M&A and investmentM&A9 records
Investments5 records
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Lundbeck
What does Lundbeck do?
H. Lundbeck A/S is a global pharmaceutical company that researches, develops, manufactures, and commercializes prescription drugs for psychiatric and neurological (CNS) disorders. Its marketed portfolio includes Vyepti (eptinezumab) for migraine prevention, Rexulti (brexpiprazole) for schizophrenia and major depressive disorder, Abilify Asimtufii for schizophrenia and bipolar I, Trintellix (vortioxetine), and Cipralex/Lexapro (escitalopram), while its investigational pipeline targets rare epilepsies, Parkinson's disease, multiple system atrophy, Cushing's disease, and thyroid eye disease through novel mechanisms such as anti-PACAP, anti-ACTH, 5-HT2C agonism, anti-alpha-synuclein, and CD40L blockade.
Is Lundbeck a public or private company?
Lundbeck is a public company. It is classified as public and is currently operating.
When was Lundbeck founded?
Lundbeck was founded in 1915. It employs 5,001 to 10,000 people.
Where is Lundbeck based?
Lundbeck is headquartered in Valby, Denmark, in the Europe region.
How does Lundbeck make money?
One revenue line is on record: pharmaceutical drug sales.
Who are Lundbeck's main competitors?
Direct peers on record are Otsuka Pharmaceutical, Jazz Pharmaceuticals, UCB and Neurocrine Biosciences. Broad incumbents are Biogen, AbbVie and Pfizer. Emerging players are Axsome Therapeutics and Sage Therapeutics. Recordati is listed as a regional player.
Does Lundbeck have an API?
No public API is recorded for Lundbeck.
What industry is Lundbeck in?
Lundbeck's product category is Central Nervous System Pharmaceuticals. Its primary akta.pro industry code is HLAIACAC, Neurology & CNS Specialty Pharmaceuticals, with a secondary code of HLAKAIAE, Headache & Migraine Medicine. Its SIC code is 2833.